AIM ImmunoTech Inc AIM introduced that Roswell Park Complete Most cancers Heart has reported the whole topline knowledge from its Part 1 research evaluating Ampligen (rintatolimod) as a element of a Chemokine-Modulating (CKM) routine for the remedy of early-stage triple-negative breast most cancers (TNBC).
The topline outcomes from the Part 1 research affirm the constructive findings beforehand introduced on the 2022 Society for Immunotherapy of Most cancers thirty seventh Annual Assembly in a poster presentation.
Full topline outcomes affirm that remedy was nicely tolerated, with promising scientific exercise of pathologic full response (pCR) + microinvasive residual illness (ypTmic) at 66%, akin to pembrolizumab/neoadjuvant chemotherapy (NAC).
The outcomes demonstrated that remedy was well-tolerated with principally grade 1 or 2 treatment-related adversarial occasions (TRAEs) with out dose-limiting toxicities (DLTs) or delayed or immune-related toxicities.
DLT was outlined as grade 3 or increased toxicities inside the first three weeks. Secondary endpoints included pCR charge the place 5/9 (56%) of sufferers attained pCR, and yet another attained ypTmic.
Tumor and blood biomarkers had been additionally analyzed in exploratory research.
A Part 2 research in early-stage TNBC is deliberate to find out if CKM, together with Ampligen, could also be a secure and efficient various to pembrolizumab or pembrolizumab/NAC.
Value Motion: AIM shares are up 6.26% at $0.62 on the final verify Monday.